The Experts below are selected from a list of 193545 Experts worldwide ranked by ideXlab platform

Michael J Fischer - One of the best experts on this subject based on the ideXlab platform.

  • Chronic Kidney Disease and pregnancy maternal and fetal outcomes
    Advances in Chronic Kidney Disease, 2007
    Co-Authors: Michael J Fischer
    Abstract:

    Chronic Kidney Disease complicates an increasing number of pregnancies, and at least 4% of childbearing-aged women are afflicted by this condition. Although diabetic nephropathy is the most common type of Chronic Kidney Disease found in pregnant women, a variety of other primary and systemic Kidney Diseases also commonly occur. In the setting of mild maternal primary Chronic Kidney Disease (serum creatinine

Johannes F.e. Mann - One of the best experts on this subject based on the ideXlab platform.

  • Dapagliflozin in Patients with Chronic Kidney Disease
    New England Journal of Medicine, 2020
    Co-Authors: Hiddo J.l. Heerspink, Bergur V. Stefánsson, Ricardo Correa-rotter, Glenn M. Chertow, Tom Greene, Fan Fan Hou, Johannes F.e. Mann, John J.v. Mcmurray, Magnus Lindberg, Peter Rossing
    Abstract:

    Abstract Background Patients with Chronic Kidney Disease have a high risk of adverse Kidney and cardiovascular outcomes. The effect of dapagliflozin in patients with Chronic Kidney Disease, with or...

  • Chronic Kidney Disease and cardiovascular risk epidemiology mechanisms and prevention
    The Lancet, 2013
    Co-Authors: Ron T Gansevoort, Brenda R. Hemmelgarn, Hiddo J.l. Heerspink, Johannes F.e. Mann, Ricardo Correarotter, Tazeen H Jafar, Kunihiro Matsushita, Chi Pang Wen
    Abstract:

    Since the first description of the association between Chronic Kidney Disease and heart Disease, many epidemiological studies have confirmed and extended this finding. As Chronic Kidney Disease progresses, Kidney-specific risk factors for cardiovascular events and Disease come into play. As a result, the risk for cardiovascular Disease is notably increased in individuals with Chronic Kidney Disease. When adjusted for traditional cardiovascular risk factors, impaired Kidney function and raised concentrations of albumin in urine increase the risk of cardiovascular Disease by two to four times. Yet, cardiovascular Disease is frequently underdiagnosed and undertreated in patients with Chronic Kidney Disease. This group of patients should, therefore, be acknowledged as having high cardiovascular risk that needs particular medical attention at an individual level. This view should be incorporated in the development of guidelines and when defining research priorities. Here, we discuss the epidemiology and pathophysiological mechanisms of cardiovascular risk in patients with Chronic Kidney Disease, and discuss methods of prevention.

  • Chronic Kidney Disease effects on the cardiovascular system
    Circulation, 2007
    Co-Authors: Ernesto L Schiffrin, Mark L Lipman, Johannes F.e. Mann
    Abstract:

    Accelerated cardiovascular Disease is a frequent complication of renal Disease. Chronic Kidney Disease promotes hypertension and dyslipidemia, which in turn can contribute to the progression of renal failure. Furthermore, diabetic nephropathy is the leading cause of renal failure in developed countries. Together, hypertension, dyslipidemia, and diabetes are major risk factors for the development of endothelial dysfunction and progression of atherosclerosis. Inflammatory mediators are often elevated and the renin-angiotensin system is frequently activated in Chronic Kidney Disease, which likely contributes through enhanced production of reactive oxygen species to the accelerated atherosclerosis observed in Chronic Kidney Disease. Promoters of calcification are increased and inhibitors of calcification are reduced, which favors metastatic vascular calcification, an important participant in vascular injury associated with end-stage renal Disease. Accelerated atherosclerosis will then lead to increased prevalence of coronary artery Disease, heart failure, stroke, and peripheral arterial Disease. Consequently, subjects with Chronic renal failure are exposed to increased morbidity and mortality as a result of cardiovascular events. Prevention and treatment of cardiovascular Disease are major considerations in the management of individuals with Chronic Kidney Disease.

Kuo-chun Hung - One of the best experts on this subject based on the ideXlab platform.

  • decrease in irisin in patients with Chronic Kidney Disease
    PLOS ONE, 2013
    Co-Authors: Chaoyung Wang, Kuo-chun Hung
    Abstract:

    Patients with Chronic Kidney Disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor γ coactivator 1-α–dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that Chronic Kidney Disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 Chronic Kidney Disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in Chronic Kidney Disease patients (58.59%; 95% CI 47.9%–69.2%, p<0.0001). The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine. Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level. Our results suggest that Chronic Kidney Disease patients have lower than normal irisin levels at rest. Furthermore, irisin may play a major role in affecting high-density lipoprotein cholesterol levels and abnormal energy expenditure in Chronic Kidney Disease patients.

  • Decrease in irisin in patients with Chronic Kidney Disease.
    PLOS ONE, 2013
    Co-Authors: Chaoyung Wang, Kuo-chun Hung
    Abstract:

    Patients with Chronic Kidney Disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor γ coactivator 1-α–dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that Chronic Kidney Disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 Chronic Kidney Disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in Chronic Kidney Disease patients (58.59%; 95% CI 47.9%–69.2%, p

Chaoyung Wang - One of the best experts on this subject based on the ideXlab platform.

  • decrease in irisin in patients with Chronic Kidney Disease
    PLOS ONE, 2013
    Co-Authors: Chaoyung Wang, Kuo-chun Hung
    Abstract:

    Patients with Chronic Kidney Disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor γ coactivator 1-α–dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that Chronic Kidney Disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 Chronic Kidney Disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in Chronic Kidney Disease patients (58.59%; 95% CI 47.9%–69.2%, p<0.0001). The decrease in irisin levels was inversely correlated with the levels of blood urea nitrogen and creatinine. Further association analysis revealed that irisin level is independently associated with high-density lipoprotein cholesterol level. Our results suggest that Chronic Kidney Disease patients have lower than normal irisin levels at rest. Furthermore, irisin may play a major role in affecting high-density lipoprotein cholesterol levels and abnormal energy expenditure in Chronic Kidney Disease patients.

  • Decrease in irisin in patients with Chronic Kidney Disease.
    PLOS ONE, 2013
    Co-Authors: Chaoyung Wang, Kuo-chun Hung
    Abstract:

    Patients with Chronic Kidney Disease have abnormal energy expenditure and metabolism. The mechanisms underlying altered energy expenditure in uremia are unknown and remain to be elucidated. Irisin is a peroxisome proliferator-activated receptor γ coactivator 1-α–dependent myokine, and it increases energy expenditure in the absence of changes in food intake or activity. We hypothesize that Chronic Kidney Disease patients have altered irisin levels. We measured resting irisin levels in 38 patients with stage 5 Chronic Kidney Disease and in 19 age- and sex-matched normal subjects. Plasma irisin levels were significantly decreased in Chronic Kidney Disease patients (58.59%; 95% CI 47.9%–69.2%, p

Chi Pang Wen - One of the best experts on this subject based on the ideXlab platform.

  • Chronic Kidney Disease and cardiovascular risk epidemiology mechanisms and prevention
    The Lancet, 2013
    Co-Authors: Ron T Gansevoort, Brenda R. Hemmelgarn, Hiddo J.l. Heerspink, Johannes F.e. Mann, Ricardo Correarotter, Tazeen H Jafar, Kunihiro Matsushita, Chi Pang Wen
    Abstract:

    Since the first description of the association between Chronic Kidney Disease and heart Disease, many epidemiological studies have confirmed and extended this finding. As Chronic Kidney Disease progresses, Kidney-specific risk factors for cardiovascular events and Disease come into play. As a result, the risk for cardiovascular Disease is notably increased in individuals with Chronic Kidney Disease. When adjusted for traditional cardiovascular risk factors, impaired Kidney function and raised concentrations of albumin in urine increase the risk of cardiovascular Disease by two to four times. Yet, cardiovascular Disease is frequently underdiagnosed and undertreated in patients with Chronic Kidney Disease. This group of patients should, therefore, be acknowledged as having high cardiovascular risk that needs particular medical attention at an individual level. This view should be incorporated in the development of guidelines and when defining research priorities. Here, we discuss the epidemiology and pathophysiological mechanisms of cardiovascular risk in patients with Chronic Kidney Disease, and discuss methods of prevention.